WEAVER GREGORY L 4

4 · ATOSSA THERAPEUTICS, INC. · Filed Jul 7, 2021

Form 4

Period: 2021-07-02

Director

Transactions

Exercise/Conversion
Common Stock
2021-07-02$5.64/sh+4,581$25,837→ 4,581 total
Exercise/Conversion
Common Stock
2021-07-02$2.38/sh+45,000$107,100→ 49,581 total
Exercise/Conversion
Common Stock
2021-07-02$2.52/sh+45,000$113,400→ 94,581 total
Exercise/Conversion
Common Stock
2021-07-02$1.70/sh+70,000$119,000→ 164,581 total
Tax Payment
Common Stock
2021-07-02$6.40/sh−57,084$365,338→ 107,497 total
Sale
Common Stock
2021-07-02$5.58/sh−107,497$599,833→ 0 total
Exercise/Conversion
Stock Option (right to buy)
2021-07-02−4,581→ 0 total
Exercise: $5.64→ Common Stock (4,581 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-07-02−45,000→ 0 total
Exercise: $2.38→ Common Stock (45,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-07-02−45,000→ 0 total
Exercise: $2.52→ Common Stock (45,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-07-02−70,000→ 0 total
Exercise: $1.70→ Common Stock (70,000 underlying)

Footnotes (6)

[F1]Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021.
[F2]Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
[F4]These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
[F5]These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
[F6]These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date.

Documents

1 file